Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Atazanavir+ Ritonavir · 1 trial · 1 indication
Treatment Failure through Week 48 defined as virologic rebound (HIV RNA \>=400 c/mL) on or before Week 48 or study discontinuation before Week 48. Virological rebound is defined as confirmed on-treatment HIV ribonucleic acid (RNA) \>= 400 c/mL at 2 consecutive visits or last on-treatment HIV RNA \>=400 c/mL followed by discontinuation of study therapy.
| Arm | Type | Description |
|---|---|---|
| A1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Atazanavir + Ritonavir | DRUG | Capsules, Oral, ATV 300mg + RTV 100mg, once daily, 96 weeks |
Inclusion Criteria: * On continued antiretroviral (ARV) treatment, with no discontinuation periods, for the previous 6 months (24 weeks). * Absence of evidence or suspected virologic failure on antiretroviral therapy * Absence of known primary mutations in the protease gene * Only 1 highly active a...
Atazanavir is used for the treatment of HIV infections, including HIV in adults and Human Immunodeficiency Virus Type 1 (HIV-1) infection. It is a small molecule developed by Bristol-Myers Squibb Company for the infectious disease therapeutic area.
Atazanavir is a protease inhibitor used against HIV. It works by inhibiting the HIV protease enzyme, which is essential for the virus to mature and become infectious. This mechanism helps reduce viral replication in people with HIV infections.
Atazanavir is developed by Bristol-Myers Squibb Company, which trades under the ticker BMY. The company is conducting clinical research on this small molecule for the treatment of HIV infections.
Atazanavir is in Phase 3 clinical development. It is an investigational drug for HIV infections and is not yet approved by regulatory authorities. The development program includes completed trials across multiple phases.
Atazanavir has been studied in clinical trials including NCT00135434, NCT00357240, NCT00365339, and NCT00393328. These trials investigated its effects on glucose and insulin metabolism, drug interactions with proton pump inhibitors and famotidine, and bioequivalence of its 300 mg capsule formulation.
Atazanavir is the generic name for the drug also known as Reyataz. It is an HIV protease inhibitor developed by Bristol-Myers Squibb Company for the treatment of HIV infections in adults.